Novo Nordisk says semaglutide cut obesity rates in young children in trial

2

COPENHAGEN, Sept 7 (Reuters) – Novo Nordisk said on Monday that in a late-stage trial, 40.4% of children aged 6 to under 12 treated with semaglutide, the active ingredient in its blockbuster

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)